Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced …
Sep 12, 2024 · FOSTER CITY, Calif.-- (BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the results of an interim analysis from a second pivotal Phase 3 clinical trial investigating the use of the company’s twice-yearly injectable HIV-1 …
Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy …
Jun 20, 2024 · Gilead recognizes the importance of helping to enable access in order for twice-yearly lenacapavir for PrEP, if approved by regulatory authorities, to achieve the broadest impact.
Gilead Presents Full PURPOSE 2 Data Results for Twice Yearly ...
2 days ago · FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is studying twice-yearly lenacapavir, the company’s injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention among a broad and geographically diverse range of cisgender men and ...
Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly ...
1 day ago · FOSTER CITY, Calif., November 13, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which ...
Twice-yearly shot proves successful at preventing HIV infection …
Jul 24, 2024 · The twice-yearly injection of the drug lenacapavir can provide total protection against HIV infections, demonstrating 100% efficacy in Phase 3 trial data released by drugmaker Gilead and...
Gilead Sciences, Inc. - Twice-Yearly Lenacapavir Demonstrates …
Jul 24, 2023 · These latest findings underscore the role of lenacapavir, the first long-acting injectable HIV treatment medication administered twice-yearly, as a person-centric therapy option and its transformative potential impact on the future of coordinated HIV clinical care.
Gilead Sciences, Inc. - Full Efficacy and Safety Results for Gilead ...
Jul 24, 2024 · Detailed data from the trial’s interim analysis announced in June showed that lenacapavir, the company’s twice-yearly injectable HIV-1 capsid inhibitor, demonstrated zero infections, 100% efficacy and superiority to background HIV incidence for the investigational use of HIV prevention in cisgender women (women assigned female at birth).
Twice-a-year injection reduced risk of HIV infection by 96%, drug …
Sep 12, 2024 · In a Phase 3 clinical trial, 99.9% of participants who took a twice-a-year injection of lenacapavir for HIV prevention did not acquire an infection, according to data from drugmaker Gilead...
Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly
2 days ago · – Gilead Spearheading Lenacapavir Access Strategies to Ensure Scientific Innovation Translates to Global Access and Real-World Impact ... BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and ...
Gilead Lenacapavir cut HIV infections by 96% in trial
Sep 12, 2024 · Gilead ’s twice-yearly shot reduced HIV infections by 96% in a second large study, the company said Thursday. The positive phase-three trial data on lenacapavir sets the stage for likely approval...